Connection

Co-Authors

This is a "connection" page, showing publications co-authored by SAMIR HANASH and ANIRBAN MAITRA.
Connection Strength

1.876
  1. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021 03; 160(4):1373-1383.e6.
    View in: PubMed
    Score: 0.189
  2. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol. 2020 Nov; 4:426-436.
    View in: PubMed
    Score: 0.188
  3. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):372-379.
    View in: PubMed
    Score: 0.168
  4. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun. 2019 01 16; 10(1):254.
    View in: PubMed
    Score: 0.166
  5. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4).
    View in: PubMed
    Score: 0.146
  6. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PLoS One. 2016; 11(3):e0152300.
    View in: PubMed
    Score: 0.136
  7. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.129
  8. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 2024 Nov 01; 604:217245.
    View in: PubMed
    Score: 0.061
  9. Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. bioRxiv. 2024 Aug 08.
    View in: PubMed
    Score: 0.061
  10. A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity Over CA19-9 Alone. bioRxiv. 2024 May 26.
    View in: PubMed
    Score: 0.060
  11. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024 03 07; 73(4):639-648.
    View in: PubMed
    Score: 0.059
  12. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Clin Chem. 2024 01 04; 70(1):102-115.
    View in: PubMed
    Score: 0.058
  13. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med. 2023 09 19; 4(9):101194.
    View in: PubMed
    Score: 0.057
  14. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration. bioRxiv. 2023 Aug 15.
    View in: PubMed
    Score: 0.057
  15. CES2 sustains HNF4a expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Mol Metab. 2022 02; 56:101426.
    View in: PubMed
    Score: 0.051
  16. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2513-2523.
    View in: PubMed
    Score: 0.046
  17. Plasma-Derived Extracellular Vesicles Convey Protein Signatures that Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. Cancers (Basel). 2020 May 02; 12(5).
    View in: PubMed
    Score: 0.045
  18. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
    View in: PubMed
    Score: 0.043
  19. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
    View in: PubMed
    Score: 0.042
  20. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018 01 01; 29(1):223-229.
    View in: PubMed
    Score: 0.039
  21. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10202-10207.
    View in: PubMed
    Score: 0.038
  22. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.